Core Viewpoint - The company will present Phase II clinical data for its novel fully human only heavy chain anti-CTLA-4 antibody, HBM4003, in combination with Tislelizumab for microsatellite stable metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) annual meeting in Berlin from October 17 to October 21, 2025 [1] Group 1 - HBM4003 is developed from the HCAb Harbour Mice® platform and is the first fully human only heavy chain antibody to enter clinical stages globally [1] - Compared to traditional anti-CTLA-4 antibodies, HBM4003 shows significantly enhanced Treg cell clearance and optimized pharmacokinetics, contributing to improved safety [1] - HBM4003 enhances antibody-dependent cellular cytotoxicity (ADCC), increasing the potential for selective clearance of intratumoral Treg cells, which may overcome efficacy and toxicity limitations of existing CTLA-4 therapies [1] Group 2 - The company has initiated a global development plan for HBM4003 targeting various solid tumors, employing an adaptive treatment design [1] - Positive efficacy and safety data have been observed in clinical trials for advanced solid tumors, both as monotherapy and in combination with PD-1 inhibitors for melanoma, colorectal cancer, neuroendocrine cancer, and hepatocellular carcinoma [1]
和铂医药-B(02142)于2025年ESMO大会公布HBM4003联合替雷利珠单抗治疗微卫星稳定型转移性结直肠癌的II期临床数据